Monday, 18 Feb 2019

You are here

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Reuters reports that the panel voted 16-1 in favor of the monthly injection developed jointly by UCB.

The FDA panel hearing was prompted by earlier studies that resulted in a July 2018 complete response letter for CV safety concerns. Panelists expressed concerns about the safety data, but nonetheless favored drug approval based on impressive efficacy data.  Most called for more post-marketing studies to further evaluate the long-term safety.

The FDA and sponsor presented data proving the effectiveness of romosozumab in postmenopausal osteoporosis, reducing vertebral fracture risk and trending towards a lower risk of non-vertebral fractures. 

Evenity, chemically known as romosozumab, belongs to a new class of drugs known as sclerostin inhibitors and is administered as a monthly subcutaneous injection. 

The FDA is not mandated to follow the recommendation of the panel, but generally does.

The meeting agenda, panel list and briefing documents can be found at the FDA website.

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

FDA approved  romosozumab .it inhibits sclerostin .as all of us know, physiologically sclerostin inhibits WNT signaling pathway. Physiologically WNT signaling pathway leads to increased bone when we inhibit sclerostin to treat osteoporosis,inhibition of WNT signaling pathway will be removed that leads to increased bone formation and it will be worsen osteophyte formation  in osteoarthritic patients...
Osteonabolic agents most notably Romosuzumab not generally recommended as the first line for the treatment of osteoporosis, because of their substantial cost.Osteoanabolic treatment recommended in following individuals: (1) severe osteoporosis with high risk of fracture, (2) treatment failure with alternative osteoporosis agents with good adherent to treatment ( BMD loss or Fx), (3) contraindications or intolerance to other osteoporosis agents, and (4) GIOP..

More Like This

Older Men Less Likely to be Assessed and Treated for Osteoporosis

A study from the University of Washington in Seattle find that men with osteoporosis were less likely to be assessed by dual-energy X-ray absorptiometry (DXA); vitamin D measurements and were less like to receive calcium/vitamin D and bisphosphonate prescriptions. 

Hip Replacements Lasting 25 Years

Lancet reports that, based on a literature review and metanalysis, patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

In the USA, there is an estimated 400,000 total hip arthroplasties (THA) annually. UK invesigators set out to answer the question: how long does a hip replacement last?

Opioid Use in Osteoarthritis Varies by State

A study in Arthritis & Rheumatology shows that there is substantial statewide variation in rates of treatment with long‐term opioid therapy in osteoarthritis - not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

Vertebroplasty and Kyphoplasty Shown to Be Ineffective

There are approximately 750,000 new vertebral compression fractures each year in the United States, with resultant acute and chronic back pain in over one‐third of patients with vertebral fractures (VF).  Both percutaneous vertebroplasty or balloon kyphoplasty have been advocated as useful means of restoring vertebral height and strength capable of reducing pain in symptomatic patients.

Heberden’s Nodes Predict Knee OA Progression

Hand and knee osteoarthritis are considered to be clinically and pathogenically different and distinct, but a new study suggests that Heberden's nodes (HNs) can predict MRI‐based knee osteoarthritis (OA) progression.

An NIH study of 575 subjects included clinical examination with evaluation of HNs at baseline and knee MRI at baseline and 24‐month.